IRLAB Therapeutics AB (publ) Capital Reinvestment Ratio

Latest as of September 2021: 0.00x

IRLAB Therapeutics AB (publ) capital reinvestment ratio. IRLAB Therapeutics AB (publ) (IRLAB-A) has a Capital Reinvestment Ratio of 0.00x as of September 2021, meaning it reinvests 0% of its operating cash flow (Skr202.83 Million) in capital expenditures (Skr137.00K). Check IRLAB Therapeutics AB (publ) total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

0.00x

Capex / Operating Cash Flow

Operating Cash Flow

Skr202.83 Million

SEK

Capital Expenditures

Skr137.00K

SEK

Data as of

Sep 2021

Most recent filing

Capital Reinvestment Ratio of IRLAB Therapeutics AB (publ) (2021–2021)

Capital reinvestment ratio of IRLAB Therapeutics AB (publ) from 2021 to 2021. This chart tracks IRLAB Therapeutics AB (publ)'s Capital Reinvestment Ratio across 1 annual periods. Also explore IRLAB Therapeutics AB (publ) net asset momentum to track the company's year-over-year net asset growth rate.

IRLAB Therapeutics AB (publ) Capital Reinvestment Ratio by Year (2021–2021)

IRLAB Therapeutics AB (publ) capital reinvestment ratio by year from 2021 to 2021. For the full cash flow conversion analysis, see IRLAB-A cash flow metrics.

Year	Reinvestment Ratio	Operating CF (SEK)	Capital Expenditures	YoY Change
2021	0.01x	Skr128.64 Million	Skr708.00K	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow